. Author manuscript; available in PMC: 2012 Oct 1.

Published in final edited form as: Urology. 2011 Aug 5;78(4):970.e15–970.e20. doi: 10.1016/j.urology.2011.05.035

Table 1. Clinicopathological characteristics of prostate cancer cases.

1121 patients were included in this study; however, detailed clinical data was available for 1033. For the purposes of this table, percentages are calculated utilizing 1033 patients.

Variable	Cases (n=1033)

European ancestry	100%

Median age (years) at prostate cancer diagnosis	61 (Range: 37–87)

Median pre-treatment PSA (ng/mL)	4.9 (Range: 0–63.6)

Clinical stage T1c	762 (73.8%)

Biopsy Gleason score
≤6	698 (67.6%)
7	285 (27.6%)
8–10	50 (4.8%)

Organ-confined disease (≤T2)	830 (80.3%)

Prostatectomy Gleason score
≤6	531 (51.4%)
7	443 (42.9%)
8–10	59 (5.7%)

Positive surgical margins	117 (11.3%)

Extracapsular extension (T3a)	29 (2.8%)

Seminal vesicle invasion	47 (4.5%)

Lymph node metastases	10 (1.0%)